JPH0729941B2 - 眼の組織中に目薬を保持するための薬剤 - Google Patents

眼の組織中に目薬を保持するための薬剤

Info

Publication number
JPH0729941B2
JPH0729941B2 JP3040134A JP4013491A JPH0729941B2 JP H0729941 B2 JPH0729941 B2 JP H0729941B2 JP 3040134 A JP3040134 A JP 3040134A JP 4013491 A JP4013491 A JP 4013491A JP H0729941 B2 JPH0729941 B2 JP H0729941B2
Authority
JP
Japan
Prior art keywords
sulfate
drug
glucan
cyclodextrin
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3040134A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04211615A (ja
Inventor
フォークマン ジューダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JPH04211615A publication Critical patent/JPH04211615A/ja
Publication of JPH0729941B2 publication Critical patent/JPH0729941B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
JP3040134A 1990-03-07 1991-03-06 眼の組織中に目薬を保持するための薬剤 Expired - Lifetime JPH0729941B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/489,680 US5227372A (en) 1990-03-07 1990-03-07 Method for retaining ophthalmological agents in ocular tissues
US07/489680 1990-03-07

Publications (2)

Publication Number Publication Date
JPH04211615A JPH04211615A (ja) 1992-08-03
JPH0729941B2 true JPH0729941B2 (ja) 1995-04-05

Family

ID=23944834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3040134A Expired - Lifetime JPH0729941B2 (ja) 1990-03-07 1991-03-06 眼の組織中に目薬を保持するための薬剤

Country Status (10)

Country Link
US (1) US5227372A (de)
EP (1) EP0447351B1 (de)
JP (1) JPH0729941B2 (de)
KR (1) KR910016315A (de)
AT (1) ATE132741T1 (de)
AU (1) AU636451B2 (de)
CA (1) CA2037624A1 (de)
DE (1) DE69116186D1 (de)
IE (1) IE910658A1 (de)
NZ (1) NZ237165A (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1993005777A1 (fr) * 1991-09-18 1993-04-01 Fujisawa Pharmaceutical Co., Ltd. Preparation transoculaire
ATE205092T1 (de) * 1992-01-30 2001-09-15 Takeda Chemical Industries Ltd Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
TW251236B (de) * 1992-09-10 1995-07-11 Ciba Vision Ag
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
US5662919A (en) * 1994-11-21 1997-09-02 Alcon Laboratories, Inc. Sulfated polyvinyl alcohol polymers to stabilize pharmaceutical drug compounds
US5710148A (en) * 1995-03-06 1998-01-20 Senju Pharmaceuticals Co., Ltd. Corneal opacification inhibitory composition
US5744154A (en) * 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
US5686095A (en) * 1995-10-23 1997-11-11 Price, Jr.; Francis W. Method of treating canker sores
DE19539532C2 (de) * 1995-10-24 1999-02-25 Mann Gerhard Chem Pharm Fab Ophthalmisches Cromoglicat-Gelpräparat
EP1003555A1 (de) * 1997-04-23 2000-05-31 The University of Otago Kontrollierte freisetzung von opthalmischen zusammensetzungen
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
JP2002523475A (ja) 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
ATE259231T1 (de) * 1999-04-29 2004-02-15 Alza Corp Liposomenzusammensetzungen zur verbesserten wirkstoffzurückhaltung
JP2001158750A (ja) * 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及び抗アレルギー薬の持続性向上方法
US6265435B1 (en) 2000-03-07 2001-07-24 Hans Rosenkoetter Method for enhancing corneal penetration by water soluble ophthalmic drugs
RU2177801C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Средство, ингибирующее ангиогенез при заболеваниях органа зрения
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
EP1476135A1 (de) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmische formulierung mit gummi-system
EP1496916A2 (de) * 2002-04-09 2005-01-19 Greenville Hospital System Metastasen-modulierende wirkung von hochsulfierten oligosacchariden
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
CL2008003120A1 (es) 2007-11-01 2009-10-09 Acucela Inc Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
JP5890182B2 (ja) * 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
WO2011123180A1 (en) 2010-04-03 2011-10-06 Praful Doshi Medical devices including medicaments and methods of making and using same
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN110621320B (zh) 2017-05-17 2023-03-17 Tx医生公司 青光眼的治疗
EP3810659A1 (de) * 2018-06-20 2021-04-28 DuPont Industrial Biosciences USA, LLC Polysaccharidderivate und zusammensetzungen damit

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923704A (en) * 1957-05-15 1960-02-02 Hoffmann La Roche Cycloamylose sulfates and derivatives thereof
US3754925A (en) * 1970-03-24 1973-08-28 Takeda Chemical Industries Ltd New thermo gelable polysaccharide containing foodstuffs
DK135268A (de) * 1973-02-09
JPS5036422A (de) * 1973-08-07 1975-04-05
JPS5366442A (en) * 1976-11-18 1978-06-13 Takuma Sasaki Antitumors
JPS5583798A (en) * 1978-12-19 1980-06-24 Takuma Sasaki (1,3)-beta-d-glucan derivative
EP0244178A3 (de) * 1986-04-28 1989-02-08 Iolab, Inc Intraokuläre Mittel und Verfahren zu deren Verwendung
EP0261719A3 (de) * 1986-09-23 1990-10-10 Akzo N.V. Thermochemischlumineszierende Komplexe von Cyclodextrinen
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
DE3740838A1 (de) * 1987-11-27 1989-06-08 Schering Ag Cyclodextrinclathrate von 5-cyano-prostacyclinderivaten und ihre verwendung als arzneimittel
EP0325199B1 (de) * 1988-01-19 1993-10-27 Takeda Chemical Industries, Ltd. Fumagillin als angiostatisches Mittel
CN1038304C (zh) * 1988-01-19 1998-05-13 摩塞斯·朱旦·福克迈 生长抑制组合物的制备方法
US5019562A (en) * 1988-01-19 1991-05-28 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Growth inhibiting agent and the use thereof
US5007967A (en) * 1988-08-15 1991-04-16 American Maize-Products Company Separation and purification of branched beta cyclodextrins

Also Published As

Publication number Publication date
JPH04211615A (ja) 1992-08-03
US5227372A (en) 1993-07-13
AU636451B2 (en) 1993-04-29
KR910016315A (ko) 1991-11-05
EP0447351B1 (de) 1996-01-10
NZ237165A (en) 1992-10-28
CA2037624A1 (en) 1991-09-08
ATE132741T1 (de) 1996-01-15
AU7139691A (en) 1991-09-12
DE69116186D1 (de) 1996-02-22
IE910658A1 (en) 1991-09-11
EP0447351A1 (de) 1991-09-18

Similar Documents

Publication Publication Date Title
EP0447351B1 (de) Medikament zum Halten ophthalmologischer Mittel im Augengewebe und Verfahren zu seiner Herstellung
AU704353B2 (en) Liquid ophthalmic sustained release delivery system
Loftssona et al. Cyclodextrins in ophthalmic drug delivery
US5612027A (en) Controlled release of miotic and mydriatic drugs in the anterior chamber
EP0660717B1 (de) Aminosteroide zur Verwendung in der Augenheilkunde
FI97777C (fi) Menetelmä silmätipoiksi tarkoitetun koostumuksen valmistamiseksi
US5494901A (en) Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
WO1997028833A1 (en) Methods and compositions for the modulation of cell proliferation and wound healing
WO1996011003A1 (en) Ophthalmic and aural compositions containing diclofenac potassium
WO2005004877A1 (en) Inhibition of irritating side effects associated with use of a topical ophthalmic medication
PT844868E (pt) Composicoes contendo o-carboxialquil quitosano e utilizacao em oftalmologia
CN101977630B (zh) 眼药组合物
CN101312711B (zh) 不含右泛醇、钙离子和磷酸盐的药物组合物以及钙螯合剂和眼科相容粘度调节剂的应用
MXPA04005390A (es) Agente oftalmico que contiene heparina.
Bernatchez et al. Use of hyaluronic acid in ocular therapy
AU2011292160B2 (en) Ophthalmic formulations of squalamine
US5948401A (en) Cationic therapeutic systems
WO2007103782A2 (en) Pharmaceutical latrunculin formulations
RU2284181C2 (ru) Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
KR20040011426A (ko) 수술용 비흡출 전이성 점탄물
Sajini et al. Plant polysaccharides in ocular drug delivery
KR0159640B1 (ko) 도파민 수용기 자극제를 포함하는 근시 및 녹내장 치료용 안과 제형
EP0888770A1 (de) Arzneizubereitungen enthaltend kationische Polysaccharide und kationische Arzneimittel
Makhijani Revolutionizing Glaucoma Care: Innovative Latanoprost Drug Delivery Takes Aim at Vision Loss
CN115227882A (zh) 一种具有亲水-抗凝药物缓释协同功能的青光眼引流支架及其制备方法与应用

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 19950912